兰州大学机构库
Prognoses of Patients Treated With Surgical Therapy Versus Continuation of Local-Plus-Systemic Therapy Following Successful Down-Staging of Intermediate-Advanced Hepatocellular Carcinoma: A Multicenter Real-World Study
2023-10-24
Online publication date2023-10
Source PublicationONCOLOGIST   Impact Factor & Quartile
ISSN1083-7159 ; 1549-490X
EISSN1549-490X
page numbers11
AbstractBackground The difference in the prognoses between treatment with surgical therapy and continuation of local-plus-systemic therapy following successful down-staging of intermediate-advanced hepatocellular carcinoma (HCC) remains unclear.Methods Data of 405 patients with intermediate-advanced HCC treated at 30 hospitals across China from January 2017 to July 2022 were retrospectively reviewed. All patients received local-plus-systemic therapy and were divided into the surgical (n = 100) and nonsurgical groups (n = 305) according to whether they received surgical therapy. The differences between long-term prognoses of the 2 groups were compared. Subgroup analysis was performed in 173 HCC patients who met the criteria for surgical resection following down-staging.Results Multivariable analysis of all patients showed that surgical therapy, hazard ratio (HR): 0.289, 95% confidence interval, CI, 0.136-0.613) was a protective factor for overall survival (OS), but not for event-free survival (EFS). Multivariable analysis of 173 intermediate-advanced HCC patients who met the criteria for surgical resection after conversion therapy showed that surgical therapy (HR: 0.282, 95% CI, 0.121-0.655) was a protective factor for OS, but not for EFS. Similar results were obtained after propensity score matching. For patients with Barcelona Clinic Liver Cancer stage B (HR: 0.171, 95% CI, 0.039-0.751) and C (HR: 0.269, 95% CI, 0.085-0.854), surgical therapy was also a protective factor for OS.Conclusions Overall, for patients with intermediate-advanced HCC who underwent local-plus-systemic therapies, surgical therapy is a protective factor for long-term prognosis and can prolong OS, and for those who met the surgical resection criteria after conversion therapy, surgical therapy is recommended. This study included 405 patients with intermediate-advanced HCC from 30 hospitals across China and investigated the difference in prognoses between treatment with surgical therapy and continuation of local-plus-systemic therapy following successful down-staging of intermediate-advanced hepatocellular carcinoma.
Keywordhepatocellular carcinoma conversion therapy surgical therapy prognosis protective factor
PublisherOXFORD UNIV PRESS
DOI10.1093/oncolo/oyad277
Indexed BySCIE
Language英语
WOS Research AreaOncology
WOS SubjectOncology
WOS IDWOS:001087871400001
Original Document TypeArticle ; Early Access
PMID 37874924
Citation statistics
Document Type期刊论文
Identifierhttps://ir.lzu.edu.cn/handle/262010/568237
Collection兰州大学
Corresponding AuthorXu, Li; Sun, Huichuan; Wang, Kui
Affiliation
1.Naval Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Hepat Surg 2, Affiliated Hosp 3, Shanghai 200438, Peoples R China;
2.Fudan Univ, Dept Liver Surg & Transplantat, Liver Canc Inst, Shanghai 200032, Peoples R China;
3.Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China;
4.Sun Yat Sen Univ, Canc Ctr, Dept Liver Surg, Guangzhou 510060, Peoples R China;
5.Guangxi Med Univ Canc Hosp, Hepatobiliary Surg Dept, Nanning, Peoples R China;
6.Zhejiang Univ, Sir Run Run Shaw Hosp, Inst Minimally Invas Surg, Coll Med,Dept Gen Surg, Hangzhou, Peoples R China;
7.Xi An Jiao Tong Univ, Dept Hepatobiliary Surg, Hosp 1, Xian, Peoples R China;
8.Tianjin Med Univ Canc Inst & Hosp, Dept Hepatobiliary Surg, Tianjin, Peoples R China;
9.Cent South Univ, Xiangya Hosp, Dept Hepat Surg, Changsha, Hunan, Peoples R China;
10.Lanzhou Univ, Dept Gen Surg, Hosp 1, Lanzhou, Peoples R China;
11.Zhengzhou Univ, Hepatobiliary & Pancreat Surg, Affiliated Hosp 1, Zhengzhou, Peoples R China;
12.Fujian Med Univ, Dept Hepatobiliary Surg, Mengchao Hepatobiliary Hosp, Fuzhou, Peoples R China;
13.Chinese Acad Med Sci, Peking Union Hosp, Dept Hepatobiliary Surg, Beijing, Peoples R China;
14.Minist Educ Beijing, Hepatopancreatobiliary Surg Dept 1, Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China;
15.Dalian Med Univ, Dept Gen Surg, Affiliated Hosp 1, Dalian, Peoples R China;
16.Anhui Med Univ, Hepatobiliary & Pancreat Surg, Affiliated Hosp 1, Hefei, Peoples R China;
17.Shandong Univ, Qilu Hosp, Dept Gen Surg, Jinan, Peoples R China;
18.Army Med Univ, Third Mil Med Univ, Southwest Hosp, Inst Hepatobiliary Surg, Chongqing, Peoples R China;
19.Shandong first Med Univ, Dept Hepatobiliary Surg, Affiliated Canc Hosp, Jinan, Peoples R China
Recommended Citation
GB/T 7714
Liu, Jianwei,Zhu, Xiaodong,Pan, Yangxun,et al. Prognoses of Patients Treated With Surgical Therapy Versus Continuation of Local-Plus-Systemic Therapy Following Successful Down-Staging of Intermediate-Advanced Hepatocellular Carcinoma: A Multicenter Real-World Study[J]. ONCOLOGIST,2023.
APA Liu, Jianwei.,Zhu, Xiaodong.,Pan, Yangxun.,Zhong, Jianhong.,Jin, Renan.,...&Wang, Kui.(2023).Prognoses of Patients Treated With Surgical Therapy Versus Continuation of Local-Plus-Systemic Therapy Following Successful Down-Staging of Intermediate-Advanced Hepatocellular Carcinoma: A Multicenter Real-World Study.ONCOLOGIST.
MLA Liu, Jianwei,et al."Prognoses of Patients Treated With Surgical Therapy Versus Continuation of Local-Plus-Systemic Therapy Following Successful Down-Staging of Intermediate-Advanced Hepatocellular Carcinoma: A Multicenter Real-World Study".ONCOLOGIST (2023).
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Altmetrics Score
Google Scholar
Similar articles in Google Scholar
[Liu, Jianwei]'s Articles
[Zhu, Xiaodong]'s Articles
[Pan, Yangxun]'s Articles
Baidu academic
Similar articles in Baidu academic
[Liu, Jianwei]'s Articles
[Zhu, Xiaodong]'s Articles
[Pan, Yangxun]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[Liu, Jianwei]'s Articles
[Zhu, Xiaodong]'s Articles
[Pan, Yangxun]'s Articles
Terms of Use
No data!
Social Bookmark/Share
No comment.
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.